Premium
Proof of concept for claudin‐targeted drug development
Author(s) -
Suzuki Hidehiko,
Kondoh Masuo,
Takahashi Azusa,
Yagi Kiyohito
Publication year - 2012
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2012.06503.x
Subject(s) - claudin , cls upper limits , tight junction , enterotoxin , immune system , chemistry , immunization , biology , computational biology , cancer research , medicine , microbiology and biotechnology , immunology , biochemistry , escherichia coli , gene , optometry
Claudins (CLs) are a family of tetra‐integral membrane proteins that are a key structural and functional component of tight junctions. CLs are overexpressed in some malignant tumors. Claudin‐4 is highly expressed in the epithelial cells covering mucosal immune tissues. CLs may therefore be a potential target for improving drug absorption, treating cancer, and developing mucosal vaccine. Research using Clostridium perfringens enterotoxin has resulted in proofs of concept for CL‐targeted drug development. A platform for the creation of CL binders, such as immunization of CL and preparation of CL proteins, is now beginning to be established.